688180 君实生物
2025/12 -
人民幣(K¥)

变动
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入2,498,42028.23%1,502,5501,453,4934,024,8411,594,897
减:营业总成本3,444,3637.11%3,811,8604,102,9314,728,2603,307,229
    其中:营业成本466,50513.59%540,976504,3081,244,540372,531
               财务费用65,273-45,300.58%(67,086)(80,955)31,36621,186
               资产减值损失(98,098)11.25%(126,314)(21,974)(13,647)(4,227)
公允价值变动收益57,210-219.99%(149,177)(9,277)112,93346,042
投资收益(106,417)351.80%73,990(41,932)(47,187)(5,621)
    其中:对联营企业和合营企业的投资收益(116,102)231.47%(60,485)(71,031)(48,463)(3,805)
营业利润(999,463)-25.35%(2,457,442)(2,665,914)(558,275)(1,656,082)
利润总额(1,023,274)-24.62%(2,491,695)(2,677,184)(595,000)(1,672,429)
减:所得税费用(13,881)-161.55%43,995(93,107)135,533(3,822)
净利润(1,009,393)-26.86%(2,535,689)(2,584,077)(730,534)(1,668,607)
减:非控股权益(134,219)35.33%(252,257)(196,028)(9,624)0
股东净利润(875,174)-31.68%(2,283,432)(2,388,050)(720,910)(1,668,607)

市场价值指针
每股收益 (元) *-0.870-33.08%-2.320-2.600-0.810-2.030
每股派息 (元) *------------
每股净资产 (元) *5.874-1.21%7.2609.6508.7206.679
审计意见 #标准无保留意见标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容